EGFR-IN-31
Modify Date: 2024-04-12 00:07:11
EGFR-IN-31 structure
|
Common Name | EGFR-IN-31 | ||
|---|---|---|---|---|
| CAS Number | 2701563-03-1 | Molecular Weight | 569.67 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C32H36FN7O2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of EGFR-IN-31EGFR-IN-31 is a potent inhibitor of EGFR. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-31 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185298A1, compound 2)[1]. |
| Name | EGFR-IN-31 |
|---|
| Description | EGFR-IN-31 is a potent inhibitor of EGFR. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-31 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185298A1, compound 2)[1]. |
|---|---|
| Related Catalog | |
| References |
[1]. Jiaqi Hu, et al. Egfr tyrosine kinase inhibitors and their uses. Patent WO2021185298A1. |
| Molecular Formula | C32H36FN7O2 |
|---|---|
| Molecular Weight | 569.67 |